Financials

News Ideas Discussions Technicals Seasonals

ALZ fundamentals

Overview Statements Statistics Dividends Earnings Revenue

Key facts

—

—

—

—

—

—

—

—

About

Alzinova AB engages in the research and development of drugs for treatment of Alzheimer's disease. It focuses on the development of oligomer-directed vaccine and monoclonal antibody specifically for the synapse-damaging oligomers. The company was founded by Anders Sandberg and Thorleif Roland Hard on August 17, 2011 and is headquartered in Molndal, Sweden.

Valuation

Fundamental metrics to determine fair value of the stock

Summary

No data available

There's currently no market capitalization, revenue or net income data to show.

Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

No dividends

ALZ has never paid dividends and has no current plans to do so.

Financial health

Financial position and solvency of the company